In addition to inducing paclitaxel resistance, the erbB2/erbB3/PI-3 K/Akt signaling also results in resistance to hormonal therapy [44] and other chemotherapy [45] in breast cancer treatment. The gene discussed is ERBB2; the disease is breast carcinoma.